InsidersTradesSigma
Follow the Acadia Pharmaceuticals INC share price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Acadia Pharmaceuticals INC has recorded 217 reports. Market capitalisation: €4.6bn. The latest transaction was filed on 7 August 2026 (Cession). Among the most active insiders: Schneyer Mark C.. Every trade is accessible without an account.
217
Insider Decl.
n/a
Thresholds
€172,971
5 ops.
Buy Volume
€9m
65 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Acadia Pharmaceuticals INC Buy (bullish), based on 20 analysts. Average price target: US$32.95.
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,035 of 29,062 companies
68.5
score / 100
Value46
Quality91
FCF yld2.1%
Earn yld7.8%
EV/EBITDA43.2x
ROE36%
Gross mgn92%
Net mgn36%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 7 August 2026
Declarations217 total
5,000 shares@ US$29.00Common StockSEC:0001899977-26-000008:3
9,292 shares@ US$29.3375Common StockSEC:0001899977-26-000008:4
5,849 shares@ US$17.84Common StockSEC:0001899977-26-000008:0
5,849 shares@ US$29.0029Common StockSEC:0001899977-26-000008:1
14,292 shares@ US$17.84Common StockSEC:0001899977-26-000008:2
5,849 shares@ US$27.150.0034% mcap8.4% of flowCommon StockSEC144:0001967940-26-000042
32,272 sharesCommon StockSEC:0001861477-26-000005:0
16,508 shares@ US$26.130.0095% mcap99.7% of flowCommon StockSEC:0001861477-26-000005:1
50 shares@ US$26.170.0000% mcap0.3% of flowCommon StockSEC:0001861477-26-000005:2
11,421 sharesCommon StockSEC:0001816160-26-000009:0
11,421 shares@ US$26.00470.0066% mcap33.9% of flowCommon StockSEC144:0001967940-26-000036
18,622 shares0Common StockSEC:0001193125-26-253632:0
18,622 shares0Common StockSEC:0001193125-26-253632:1
8,107 sharesCommon StockSEC:0001177917-26-000009:0
8,107 sharesCommon StockSEC:0001365619-26-000002:0
8,107 sharesCommon StockSEC:0001560782-26-000002:0
2,010 sharesCommon StockSEC:0001604689-26-000009:0
8,107 sharesCommon StockSEC:0001826361-26-000002:0
5,401 shares@ US$21.180.0022% mcap19.3% of flowCommon StockSEC:0001816160-26-000008:0
2,596 sharesCommon StockSEC:0001816160-26-000007:0
1,332 shares@ US$21.790.0005% mcap4.9% of flowCommon StockSEC:0001816160-26-000007:1
6,815 sharesCommon StockSEC:0001899977-26-000007:0
3,506 shares@ US$21.790.0014% mcap4.3% of flowCommon StockSEC:0001899977-26-000007:1
2,010 sharesCommon StockSEC:0001816160-26-000005:0
25 of 217 declarations
关于 Acadia Pharmaceuticals INC
ACADIA Pharmaceuticals Inc. 是一家在美国纳斯达克上市的生物制药公司，股票代码为 ACAD，是专注于美国专业医疗保健和神经科学的投资者密切关注的公司。该公司总部位于加利福尼亚州圣迭戈，致力于开发和商业化神经系统疾病和罕见病的疗法，其战略重点是治疗选择有限的服务不足的患者群体。其企业身份植根于神经科学创新和中枢神经系统疾病方面的长期专业知识。（[acadia.com](https://acadia.com/en-us/about?utm_source=openai)） Acadia 的商业产品组合以两种关键产品为核心。NUPLAZID (pimavanserin) 被公司描述为美国首个也是唯一一个获得 FDA 批准的用于治疗帕金森病精神病相关的幻觉和妄想的药物。DAYBUE (trofinetide) 是其第二个主要的商业特许经营产品：它已获批用于治疗两岁及以上成人和儿童患者的 Rett 综合征，在美国和加拿大进行商业化，并在欧洲开展监管工作。2025 年 12 月，FDA 批准了 DAYBUE STIX，这是一种 trofinetide 粉末制剂，该产品现已在美国广泛上市，增加了便利性和制剂灵活性，可能有助于推广和持续使用。（[acadia.com](https://acadia.com/en-us?utm_source=openai)） 从竞争角度来看，Acadia 作为一家专注于神经科学和罕见病的公司脱颖而出。这种专业化为其带来了显著的科学、监管和商业进入壁垒，但也带来了集中风险，因为业务严重依赖少数关键资产。公司近期披露的信息表明，发展势头显著增强：2025 年总收入超过 $1 billion，管理层上调了 2026 年业绩指引，预示着更持久的商业基础。在 2026 年第一季度，公司重申了全年业绩指引，同时报告收入持续增长。（[acadia.com](https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operating-overview?utm_source=openai)） 从地理上看，Acadia 仍主要专注于美国市场，但正在通过加拿大、欧洲以及美国以外的某些指定患者或准入途径建立国际业务。公司还在积极推进其研发管线，包括用于阿尔茨海默病精神病的 remlifanserin、用于原发性震颤的 ACP-711 以及其他专注于中枢神经系统的项目。因此，对于讲法语的投资者而言，ACAD 代表了一家拥有成熟商业资产、监管扩张潜力以及临床催化剂的专业医疗保健股票。（[acadia.com](https://acadia.com/en-us/about?utm_source=openai)）
